Clarity Medical Group Holding Limited has slated a board meeting for 15 September 2026. Directors will review and approve the audited financial statements for the fiscal years ended 31 March 2025 and 31 March 2026, as well as the interim results for the six months ended 30 September 2025. Potential declarations of final and interim dividends will also be considered during the session.
Trading in Clarity Medical’s shares has been suspended since 09:00 a.m. on 15 April 2025 and will remain halted until further notice, according to the company. The board advises shareholders and prospective investors to exercise caution when dealing in the company’s securities.
The current board comprises one executive director (Mr Jiang Bo, who also serves as Chief Executive Officer), three non-executive directors and four independent non-executive directors.
Comments